An increasing number of small biotech companies are being hatched to focus on a single disease or condition. PharmExec talks to the CEO of one such company, Eugene Williams of Dart Therapeutics.
New stakeholders, innovative technologies, and emergent synergies in government are combining to build fresh momentum behind the old issue of medication adherence. The question is will Big Pharma be flexible enough to keep pace with the changes?
Thankfully, the civil war is not a public relations issue for Big Pharma, but the long-term business implications for the Middle East region are cagey.
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva